Capricor Therapeutics (NASDAQ:CAPR) Stock Sees Heavy Put Option Buying

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) was the recipient of some unusual options trading on Thursday. Stock traders purchased 27,192 put options on the company. This represents an increase of approximately 137% compared to the average volume of 11,460 put options.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $7.57 on Friday. Capricor Therapeutics has a 52 week low of $2.96 and a 52 week high of $40.37. The stock has a 50 day moving average price of $8.02 and a two-hundred day moving average price of $19.48.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29). On average, equities analysts anticipate that Capricor Therapeutics will post -2.39 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Montanova Capital LLC lifted its position in shares of Capricor Therapeutics by 7.2% during the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. RA Capital Management L.P. boosted its holdings in Capricor Therapeutics by 99.9% during the third quarter. RA Capital Management L.P. now owns 3,014,183 shares of the biotechnology company’s stock worth $28,544,000 after purchasing an additional 1,506,339 shares during the last quarter. Jump Financial LLC grew its position in Capricor Therapeutics by 1,984.9% in the 3rd quarter. Jump Financial LLC now owns 480,286 shares of the biotechnology company’s stock worth $4,548,000 after purchasing an additional 457,250 shares in the last quarter. Bank of America Corp DE grew its position in Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its position in Capricor Therapeutics by 169.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company’s stock worth $1,930,000 after purchasing an additional 128,067 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on CAPR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Roth Capital restated a “neutral” rating and issued a $10.50 target price (up from $7.00) on shares of Capricor Therapeutics in a research report on Friday, November 13th. Piper Sandler upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a report on Tuesday, July 28th. Finally, JonesTrading raised Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Wednesday, November 11th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of “Hold” and an average price target of $30.09.

Read Our Latest Research Report on Capricor Therapeutics

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

See Also

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.